Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Cg Oncology Inc (CGON)

Cg Oncology Inc (CGON)
20.10 -0.31 (-1.52%) 13:36 ET [NASDAQ]
20.10 x 40 20.24 x 600
Realtime by (Cboe BZX)
20.10 x 40 20.24 x 600
Realtime 20.96 +0.55 (+2.69%) 09:30 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
20.04
Day High
21.20
Open 20.93
Previous Close 20.41 20.41
Volume 538,039 538,039
Avg Vol 1,296,666 1,296,666
Stochastic %K 59.45% 59.45%
Weighted Alpha -38.22 -38.22
5-Day Change +0.45 (+2.24%) +0.45 (+2.24%)
52-Week Range 14.80 - 46.99 14.80 - 46.99
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,555,589
  • Shares Outstanding, K 76,217
  • Annual Sales, $ 1,140 K
  • Annual Income, $ -88,040 K
  • EBIT $ -115 M
  • EBITDA $ -120 M
  • 60-Month Beta 1.24
  • Price/Sales 1,381.14
  • Price/Cash Flow N/A
  • Price/Book 2.14

Options Overview Details

View History
  • Implied Volatility 144.48% ( +6.19%)
  • Historical Volatility 91.06%
  • IV Percentile 99%
  • IV Rank 90.23%
  • IV High 154.72% on 05/02/24
  • IV Low 49.90% on 12/24/24
  • Put/Call Vol Ratio 0.60
  • Today's Volume 80
  • Volume Avg (30-Day) 267
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 4,920
  • Open Int (30-Day) 2,294

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.36
  • Number of Estimates 4
  • High Estimate -0.13
  • Low Estimate -0.58
  • Prior Year -0.36
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.80 +38.58%
on 04/09/25
Period Open: 27.05
28.75 -28.66%
on 03/24/25
-6.54 (-24.18%)
since 03/21/25
3-Month
14.80 +38.58%
on 04/09/25
Period Open: 30.21
31.16 -34.18%
on 01/27/25
-9.70 (-32.11%)
since 01/22/25
52-Week
14.80 +38.58%
on 04/09/25
Period Open: 33.54
46.99 -56.35%
on 05/03/24
-13.03 (-38.85%)
since 04/22/24

Most Recent Stories

More News
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

CGON : 20.10 (-1.52%)
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

CGON : 20.10 (-1.52%)
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

CGON : 20.10 (-1.52%)
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

CGON : 20.10 (-1.52%)
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

CGON : 20.10 (-1.52%)
CG Oncology Closes $238 Million Public Offering of Common Stock

CG Oncology closed a public offering of 9.2 million shares, raising $238 million for bladder cancer therapy development.Quiver AI SummaryCG Oncology, Inc., a clinical biopharmaceutical company specializing...

CGON : 20.10 (-1.52%)
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CGON : 20.10 (-1.52%)
CG Oncology Announces Pricing of Public Offering for 8 Million Shares of Common Stock at $28 Per Share

CG Oncology announces public offering of 8,000,000 shares at $28 each, expected to raise $204.4 million.Quiver AI SummaryCG Oncology, Inc. has announced the pricing of its public offering of 8 million...

CGON : 20.10 (-1.52%)
CG Oncology Announces Pricing of Public Offering

CGON : 20.10 (-1.52%)
CG Oncology Files Registration Statement for Proposed Public Offering of Common Stock

CG Oncology files for a public offering of 7.3 million shares, with additional shares from existing stockholders.Quiver AI SummaryCG Oncology, Inc., a clinical biopharmaceutical company focused on bladder...

CGON : 20.10 (-1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 22.70
2nd Resistance Point 22.18
1st Resistance Point 21.29
Last Price 20.10
1st Support Level 19.88
2nd Support Level 19.36
3rd Support Level 18.47

See More

52-Week High 46.99
Fibonacci 61.8% 34.69
Fibonacci 50% 30.90
Fibonacci 38.2% 27.10
Last Price 20.10
52-Week Low 14.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro